|
1.
|
MP VerziDJ McCulleyS De ValThe right
ventricle, outflow tract, and ventricular septum comprise a
restricted expression domain within the secondary/anterior heart
fieldDev Biol287134145200510.1016/j.ydbio.2005.08.041
|
|
2.
|
S ZaffranRG KellySM MeilhacRight
ventricular myocardium derives from the anterior heart fieldCirc
Res95261268200410.1161/01.RES.0000136815.73623.BE15217909
|
|
3.
|
F HaddadSA HuntDN RosenthalDJ MurphyRight
ventricular function in cardiovascular disease, part I: Anatomy,
physiology, aging, and functional assessment of the right
ventricleCirculation11714361448200810.1161/CIRCULATIONAHA.107.65357618347220
|
|
4.
|
F HaddadR DoyleDJ MurphySA HuntRight
ventricular function in cardiovascular disease, part II:
pathophysiology, clinical importance, and management of right
ventricular
failureCirculation11717171731200810.1161/CIRCULATIONAHA.107.65358418378625
|
|
5.
|
M StrniskovaT RavingerovaJ NeckarChanges
in the expression and/or activation of regulatory proteins in rat
hearts adapted to chronic hypoxiaGen Physiol
Biophys252541200616714773
|
|
6.
|
GY WangDT McCloskeyS TurcatoContrasting
inotropic responses to alpha1-adrenergic receptor stimulation in
left versus right ventricular myocardiumAm J Physiol Heart Circ
Physiol291H2013H2017200610.1152/ajpheart.00167.200616731650
|
|
7.
|
SC ManchandaS KrishnaswamiCombination
treatment with trimetazidine and diltiazem in stable angina
pectorisHeart78353357199710.1136/hrt.78.4.3539404250
|
|
8.
|
H SzwedZ SadowskiW ElikowskiCombination
treatment in stable effort angina using trimetazidine and
metoprolol: results of a randomized, double-blind, multicentre
study (TRIMPOL II). Trimetazidine in POLandEur Heart
J2222672274200110.1053/euhj.2001.2896
|
|
9.
|
G KoberT BuckH SievertC
VallbrachtMyocardial protection during percutaneous transluminal
coronary angioplasty: effects of trimetazidineEur Heart
J13110911151992
|
|
10.
|
X LiuY GaiF LiuTrimetazidine inhibits
pressure overload-induced cardiac fibrosis through NADPH
oxidase-ROS-CTGF pathwayCardiovasc
Res88150158201010.1093/cvr/cvq18120534773
|
|
11.
|
JN WeissP KorgeHM HondaP PingRole of the
mitochondrial permeability transition in myocardial diseaseCirc
Res93292301200310.1161/01.RES.0000087542.26971.D412933700
|
|
12.
|
AP HalestrapSJ ClarkeSA
JavadovMitochondrial permeability transition pore opening during
myocardial reperfusion - a target for cardioprotectionCardiovasc
Res61372385200410.1016/S0008-6363(03)00533-914962470
|
|
13.
|
LP LimNC LauP Garrett-EngeleMicroarray
analysis shows that some microRNAs downregulate large numbers of
target mRNAsNature433769773200510.1038/nature0331515685193
|
|
14.
|
EM SmallRJ FrostEN OlsonMicroRNAs add a
new dimension to cardiovascular
diseaseCirculation12110221032201010.1161/CIRCULATIONAHA.109.88904820194875
|
|
15.
|
Y ChengC ZhangMicroRNA-21 in
cardiovascular diseaseJ Cardiovasc Transl
Res3251255201010.1007/s12265-010-9169-720560046
|
|
16.
|
PA da Costa MartinsLJ De WindtMiR-21: A
miRaculous Socratic paradoxCardiovasc Res87397400201020562424
|
|
17.
|
B OzpolatU AkarM SteinerProgrammed cell
death-4 tumor suppressor protein contributes to retinoic
acid-induced terminal granulocytic differentiation of human myeloid
leukemia cellsMol Cancer
Res595108200710.1158/1541-7786.MCR-06-0125
|
|
18.
|
H AllgayerPdcd4, a colon cancer prognostic
that is regulated by a microRNACrit Rev Oncol
Hematol73185191201010.1016/j.critrevonc.2009.09.00119836969
|
|
19.
|
HJ BogaardR NatarajanSC HendersonChronic
pulmonary artery pressure elevation is insufficient to explain
right heart
failureCirculation12019511960200910.1161/CIRCULATIONAHA.109.88384319884466
|
|
20.
|
J KajsturaE CigolaA MalhotraAngiotensin II
induces apoptosis of adult ventricular myocytes in vitroJ Mol Cell
Cardiol29859870199710.1006/jmcc.1996.03339152847
|
|
21.
|
F CacciapuotiEchocardiographic evaluation
of right heart function and pulmonary vascular bedInt J Cardiovasc
Imaging25689697200910.1007/s10554-009-9478-619634000
|
|
22.
|
C VitaleM WajngatenB SposatoTrimetazidine
improves left ventricular function and quality of life in elderly
patients with coronary artery diseaseEur Heart
J2518141821200410.1016/j.ehj.2004.06.03415474696
|
|
23.
|
P Di NapoliAA TaccardiA BarsottiLong term
cardio-protective action of trimetazidine and potential effect on
the inflammatory process in patients with ischaemic dilated
cardiomyopathyHeart91161165200515657223
|
|
24.
|
PF KantorA LucienR KozakGD LopaschukThe
antianginal drug trimetazidine shifts cardiac energy metabolism
from fatty acid oxidation to glucose oxidation by inhibiting
mitochondrial long-chain 3-ketoacyl coenzyme A thiolaseCirc
Res86580588200010.1161/01.RES.86.5.580
|
|
25.
|
G FragassoA PalloshiP PuccettiA randomized
clinical trial of trimetazidine, a partial free fatty acid
oxidation inhibitor, in patients with heart failureJ Am Coll
Cardiol48992998200610.1016/j.jacc.2006.03.06016949492
|
|
26.
|
H TuunanenE EngblomA NaumTrimetazidine, a
metabolic modulator, has cardiac and extracardiac benefits in
idiopathic dilated
cardiomyopathyCirculation11812501258200810.1161/CIRCULATIONAHA.108.77801918765391
|
|
27.
|
M TatsuguchiHY SeokTE CallisExpression of
microRNAs is dynamically regulated during cardiomyocyte
hypertrophyJ Mol Cell
Cardiol4211371141200710.1016/j.yjmcc.2007.04.00417498736
|
|
28.
|
D SayedM HeC HongMicroRNA-21 is a
downstream effector of AKT that mediates its antiapoptotic effects
via suppression of Fas ligandJ Biol
Chem2852028120290201010.1074/jbc.M110.10920720404348
|
|
29.
|
Y ChengX LiuS ZhangMicroRNA-21 protects
against the H(2)O(2)-induced injury on
cardiac myocytes via its target gene PDCD4J Mol Cell
Cardiol475142009
|
|
30.
|
S DongY ChengJ YangMicroRNA expression
signature and the role of microRNA-21 in the early phase of acute
myocardial infarctionJ Biol
Chem2842951429525200910.1074/jbc.M109.02789619706597
|
|
31.
|
J QianX RenX WangBlockade of Hsp20
phosphorylation exacerbates cardiac ischemia/reperfusion injury by
suppressed autophagy and increased cell deathCirc
Res10512231231200910.1161/CIRCRESAHA.109.20037819850943
|
|
32.
|
P MeyerRV DesaiM MujibRight ventricular
ejection fraction <20% is an independent predictor of mortality
but not of hospitalization in older systolic heart failure
patientsInt J Cardiol1551201252012
|
|
33.
|
NF VoelkelRA QuaifeLA LeinwandRight
ventricular function and failure: report of a National Heart, Lung,
and Blood Institute working group on cellular and molecular
mechanisms of right heart
failureCirculation11418831891200610.1161/CIRCULATIONAHA.106.632208
|
